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Abstract Background: There are limited prospective data on clopidogrel resistance and
clinical outcome of patients with selective coronary drug-eluting stent (DES)
implantation.
Objective: To investigate whether clopidogrel resistance is associated with long-
term thrombotic events in patients with selective coronary DES implantation.
Methods: A total of 154 patients who underwent selective percutaneous cor-
onary intervention (PCI) with DES were enrolled in this study. Platelet aggre-
gation was measured using light transmittance aggregometry (LTA) before
clopidogrel administration (baseline) and 24 hours after loading with clopid-
ogrel 300mg. Clopidogrel resistance was defined as £10% absolute differ-
ence between baseline aggregation and post-administration aggregation. All
patients who received the same anti-platelet treatment were followed up for
1 year after discharge for the incidence of a composite endpoint consisting
of cardiovascular death, myocardial infarction (MI) and revascularization,
and secondly for the incidence of stent thrombosis.
Results: The incidence of clopidogrel resistance is 20.28% in our study popula-
tion. Patients who are complicated by diabetes mellitus, smoke, or have a higher
body mass index (BMI) tend to have clopidogrel resistance. Patients in the
clopidogrel-resistant group have significantly higher incidences of composite
endpoints (21.88% vs 4.92%; p= 0.006) and stent thrombosis (12.5% vs 1.64%;
p= 0.017) than patients in the clopidogrel-response groupduring 1-year follow-up.
Conclusions: Diabetes, smoking, and high BMI are associated with clopi-
dogrel resistance, and clopidogrel resistance indicates an increased risk of
long-term thrombotic events in patients implanted with DES.
Introduction
Anti-platelet therapy is the cornerstone man-
agement of patients with acute coronary syn-
drome (ACS), especially in patients with coro-
nary disease after coronary stenting. Dual anti-
platelet therapy with aspirin (acetylsalicylic acid)
and clopidogrel has been regarded as a standard
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anti-platelet regimen after drug-eluting stent (DES)
implantation for coronary disease.[1] Nevertheless,
a large number of cardiovascular events continue
to occur despite anti-platelet therapy. Although
poor patient compliance can account for some of
these events, particularly in those patients who
receive DES, increasing evidence indicates that
there is variability in response to anti-platelet ther-
apy and patients who have a higher level of pla-
telet reactivity are at an increased risk of recurrent
cardiovascular thrombotic events.[2] Therefore,
the concept of aspirin and clopidogrel ‘resistance’
has arisen, and it is indicated that the recurrence
of adverse cardiovascular events may be attrib-
uted to aspirin or clopidogrel resistance.[3,4] The
second-generationP2Y12blocker clopidogrel whose
safety profile is better with a lower incidence of
hematologic and liver complications has largely
replaced the first-generation P2Y12 blocker ticlopi-
dine in clinical therapy. Several clinical trials have
demonstrated that non-responsiveness to clopid-
ogrel is related to a higher risk of cardiovascular
events in patients.[5,6] However, little prospective
data are available in patients with implantation
of DES for longer follow-up periods. In the pre-
sent study, we aimed to determine clinical factors
that were associated with clopidogrel resistance
and whether clopidogrel resistance is associated
with long-term thrombotic events in patients with
selective coronary DES implantation.
Methods
Study Protocol
This study was approved by the Ethics Com-
mittee of China. 154 patients undergoing selec-
tive coronary stent implantation were enrolled
after giving written informed consent between
January 2006 and January 2008. Exclusion cri-
teria were as follows: (i) history of recent bleeding
diathesis or heparin-induced thrombocytopenia;
(ii) hematologic or malignant disorder; (iii) seri-
ous liver or kidney damage; (iv) serious infection,
tumor, or immunologic system disease; (v) cere-
brovascular event within the last 3 months;
(vi) major surgical operation within 1 week prior;
(vii) angiographically visible thrombus in target
vessels; and (viii) acute myocardial infarction
(MI) within 10 days.
All interventions were performed according to
current clinical guidelines, with the implantation
of the same type of DES (Partner, Lepu Medical
Technology, Beijing, China) and the use of glyco-
protein IIb/IIIa inhibitors at discretion of the
operator. A weight-adjusted intra-procedural un-
fractionated heparin (with a goal activated clot-
ting time of 250–300 seconds) was administered
during the procedure and was routinely disconti-
nued at the end of the procedure. A 300mg loading
dose of clopidogrel was given to all patients at
least 6 hours prior to percutaneous coronary
intervention (PCI), followed by a daily dose of
150mg for 2 weeks and then 75mg for a mini-
mum of 11.5 months. In addition, from the first
day of the procedure, all patients were admin-
istered aspirin 300mg daily for 1 month and then
100mg for the lifetime of the patient.
Platelet Aggregation
Blood samples were collected in evacuated
containers containing 3.8% sodium citrate before
clopidogrel administration (baseline) and at least
24 (24–28) hours after the loading dose (300mg)
of clopidogrel. Platelet-rich plasma (PRP) was pre-
pared by centrifugation at 1000 g for 5 minutes
and platelet-poor plasma (PPP) was prepared by
centrifugation at 4500 g for 15 minutes. The PRPs
were stimulated by adenosine diphosphate (ADP)
20mmol/L. Platelet aggregation was assessed with
a Chrono-Log Lume-Aggregometer (model 700)
and analyzed using the Aggro/Link software pack-
age (Chrono-Log Corporation, Havertown, PA,
USA). Clopidogrel resistance was defined as £10%
absolute difference between baseline aggregation
and post-administration aggregation.[7]
Clinical Follow-Up and Endpoints
All patients were followed up and drug ther-
apy compliance was monitored via telephone or
an out-patient clinic every month for 1 year after
hospital discharge. The two clinical endpoints
were as follows: (i) a composite of cardiovascular
death, MI, and revascularization; and (ii) definite
or probable stent thrombosis. Cardiovascular
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death was defined as death of acute MI, coronary
artery disease, or heart failure. The diagnosis of
MI was established in the presence of any typical
increase or decrease of cardiac biomarkers along
with clinical symptoms consistent with cardiac
ischemia, following theAmericanCollege ofCardio-
logy definition.[8] Revascularization includes bypass
surgery and PCI. The diagnosis of stent thrombosis
was made according to the Academic Research
Consortium (ARC) definitions, including definite,
probable. or possible. and acute (within 24 hours
from procedure), subacute (1–30 days), or late (30
days to 1 year). The determination of definite stent
thrombosis required the presence of a coronary
syndrome with angiographic or autopsy evidence
of thrombus or occlusion. Probable stent throm-
bosis included unexplained deaths within 1 month
after the procedure or acuteMI involving the target-
vessel territory without angiographic confirmation.
The treating physician and the investigators
who evaluated the clinical endpoints were blinded
to the results of the platelet aggregation.
Statistical Analysis
Continuous variables were presented as mean–
SD and were compared using Student’s t-test.
Categorical variables were presented as frequencies
and percentages. Patient demographic groups
were compared with the chi-squared test, or exact
tests if expected cell frequencies were small.Multi-
variate regression analysis was used to identify if
clopidogrel resistance is an independent predictor
of thrombotic events. Analysis was performed
with SPSS software, version 11.5. All statistical
analyses were two-tailed, and a probability value
of p < 0.05 was considered to be statistically sig-
nificant.
Results
Basic Characteristics of Study Population
In the study, a total of 154 patients with the im-
plantation of the same type of DESwere enrolled,
including 64 females and 90 males. The average
age was 60 years (range 30–78 years). Thirty-two
patients (20.78%) met the definition of clopido-
grel resistance. The characteristics of the study
population are presented in table I. Compared
with clopidogrel-response patients, clopidogrel-
resistant patients were more likely to have dia-
betes mellitus, smoke, and have a higher body
mass index (BMI). There were no statistically
Table I. Baseline characteristics of the study population
Clopidogrel-resistant group (n =32) Clopidogrel-response group (n =122) p-Value
Mean age–SD [y] 60 – 9 60– 10 0.855
Female [n (%)] 14 (43.75) 50 (40.98) 1.000
Dyslipidemia [n (%)] 21 (65.63) 76 (62.30) 0.838
Diabetes mellitus [n (%)] 18 (56.25) 38 (31.15) 0.024
Mean BMI –SD 25.12 –2.61 24.24 – 2.11 0.049
Hypertension [n (%)] 23 (71.88) 84 (68.85) 0.831
Smoker [n (%)] 15 (46.88) 32 (26.23) 0.031
Angiographic characteristic [n (%)]
one vessel 8 (25) 32 (26.23) 1.000
two vessels 13 (40.63) 61 (50) 0.428
multiple vessels 11 (34.38) 29 (23.77) 0.259
Medications [n (%)]
statins 29 (90.63) 107 (87.7) 0.767
b-blocker 26 (81.25) 98 (80.33) 1.000
ACEI or ARB 28 (87.5) 115 (94.26) 0.241
glycoprotein IIb/IIIA inhibitor 10 (31.25) 44 (36.07) 0.681
b-blocker =b-adrenoceptor antagonists; ACEI =angiotensin-converting enzyme inhibitor; ARB =angiotensin receptor blocker; BMI = body
mass index.
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significant differences in the other characteristics
between clopidogrel-resistant and clopidogrel-
response patients.
Clopidogrel-Resistant Patients were at Higher
Risk of Composite Endpoints and Stent
Thrombosis than Clopidogrel-Response
Patients
As shown in table II, composite endpoints oc-
curred in 13 of 154 patients (8.44%) during 1 year of
follow-up, including four cardiovascular deaths
(2.60%), five MI (3.25%), and four revasculari-
zation (2.60%). According to ARC definitions,
there were six stent thrombosis in which three
were definite (1.95%) and three were probable
(1.95%), and two (1.30%) were subacute and four
(2.60%) were late. No acute stent thrombosis oc-
curred in the patients in this study.
Clopidogrel-resistant patients were at higher
risk of composite endpoints and stent thrombosis
than clopidogrel-response patients (composite end-
points 21.88% vs 4.92%, p = 0.006; stent throm-
bosis 12.5% vs 1.64%, p = 0.017). Although there
was no statistical significance in other outcomes,
the trend associated with the clopidogrel-resistant
group seemed unfavorable.
To examine if clopidogrel resistance is an in-
dependent predictor of thrombotic events, we
adjusted for diabetes, BMI, and smoking status
using multivariate regression analysis. The result
indicated that clopidogrel resistance is an in-
dependent predictor of composite endpoints and
stent thrombosis (composite endpoints p= 0.008;
stent thrombosis p = 0.025).
Discussion and Conclusions
Clopidogrel has been regarded as an effective
anti-thrombotic drug because it has been shown
to yield a 35–60% reduction in ex vivo platelet
aggregation in normal volunteers and patients
with stable coronary disease.[4] However, there is
individual variability in platelet response to clo-
pidogrel. Thrombotic events still occurred in some
patients who were receiving regular clopidogrel
therapy and the platelet function of these patients
could not be effectively inhibited. This phenom-
enon is called ‘clopidogrel resistance’ and the exact
mechanism is not yet known.[9] A previous study
showed that the rate of clopidogrel resistance in
patients ranged between 4% and 30%, although
the definitions of clopidogrel resistance varied.[10]
In the present study, the rate of clopidogrel re-
sistance is 20.78%. The first clinical factor we
found to be associated with clopidogrel resistance
was diabetes, as described in a previous study.[11]
Mechanisms responsible for suboptimal clopidogrel-
induced anti-platelet effects in diabetic patients
include increased exposure to ADP, increased
cytosolic levels of calcium, and increased platelet
turnover.[12] Furthermore, polymorphism in the








Composite endpoint 13 (8.44) 7 (21.88) 6 (4.92) 0.006
cardiovascular death 4 (2.60) 2 (6.25) 2 (1.64) 0.191
MI 5 (3.25) 3 (9.38) 2 (1.64) 0.061
revascularization 4 (2.60) 2 (6.25) 2 (1.64) 0.191
Stent thrombosis 6 (3.90) 4 (12.5) 2 (1.64) 0.017
definite 3 (1.95) 2 (6.25) 1 (0.82) 0.110
probable 3 (1.95) 2 (6.25) 1 (0.82) 0.110
Time of stent thrombosis
acute 0 0 0
subacute 2 (1.30) 1 (3.13) 1 (0.82) 0.373
late 4 (2.60) 3 (9.38) 1 (0.82) 0.028
a Values are presented as [n (%)].
MI =myocardial infarction.
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ADP receptor or differences in the post-receptor
signaling pathway could not be excluded as an
additional explanation for clopidogrel resistance.
The second clinical factor we found associated
with clopidogrel resistance was smoking and there
are no previous data on this relationship. Clopid-
ogrel, a pro-drug, is metabolized in the liver via
the cytochrome P450 (CYP) isoenzymes CYP3-
A4 and CYP1A2, and is converted to the active
compound, which inhibits the P2Y12 ADP platelet
receptor. Lau et al.[13] have shown that hepatic
CYP3A4 activity contributed to clopidogrel re-
sistance. CYP1A2 could be activated by the poly-
cyclic aromatic hydrocarbons that exist in cigarette
smoke.[14] Furthermore, nicotine feeding could
induce hepatic CYP1A2 in rats.[15] The last clin-
ical factor we found associated with clopidogrel
resistance was BMI. It has been reported that
elevated BMI is an independent predictor of sub-
optimal platelet response to clopidogrel in patients
undergoing coronary stenting.[16] Previous data
also show that obese individuals had an enhanced
platelet function and altered metabolism of clo-
pidogrel.[17] The activity of CYP3A4 has been
shown to be reduced in overweight individuals.[18]
Feher et al.[19] have demonstrated that incidence
of clopidogrel resistance is higher in females than
in males. Sixty-four women were enrolled in this
study and we failed to find a significant difference
in the sexes between clopidogrel-resistant and
clopidogrel-response groups. Recently, it has been
indicated that polymorphism of CYP2C19 is one
possible mechanism for clopidogrel resistance.[20-23]
CYP2C19 plays a critical role in converting clo-
pidogrel into its active form, and the polymorphism
of CYP2C19 is related to the response to clopi-
dogrel and eventually influences the occurrence
of thrombotic events after PCI.
The application of DES technology to im-
prove clinical outcomes after PCI represents one
of the greatest success stories in cardiology. DES,
after coronary angioplasty and bare stent implan-
tation, has been regarded as the third milestone
in interventional cardiology. Compared with bare
stent, DES can markedly reduce the risk of re-
stenosis.[24] Dual therapy with clopidogrel and
aspirin is a standard anti-platelet therapy after
DES implantation. Generally, it is recommended
that patients with implantation of DES need to
take aspirin for the duration of their life and
clopidogrel for at least 1 year. Previous studies
have shown that clopidogrel resistance was re-
lated to the recurrence of cardiovascular events in
patients receiving PCI.[25] In the present study, we
observed that patients in the clopidogrel-resistant
group had a higher risk of composite thrombotic
events after DES implantation.
Our study has several limitations as follows:
(i) the size of the study population is small;
(ii) platelet aggregation was assessed only before
and after loading dose, and it is possible that the
response to clopidogrel would change during
the follow-up; and (iii) aspirin resistance that is
associated with clopidogrel resistance[26] was not
measured in the study.
In summary, our study showed that diabetes,
smoking, and high BMI are associated with clo-
pidogrel resistance in patients implanted with
DES. Furthermore, clopidogrel-resistant patients
were at a higher risk for composite endpoints and
stent stenosis in the 1-year follow-up. Therefore,
patients who are likely to have clopidogrel resis-
tance may need platelet monitoring and also re-
quire an adjunct anti-thrombotic treatment to
adequately inhibit platelet aggregation, especially
in a high-risk clinical setting such as PCI.
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